by Maria Zannes | Mar 3, 2026 | Press Releases
Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAI) Annual Meeting Research demonstrates the technology’s ability to identify drug antibody receptors in sputum for two leading asthma...
by Maria Zannes | Mar 1, 2026 | Publications
Academy of Allergy, Asthma and Immunology (AAAAI) 2026 Annual Meeting March 1, 2026 Authors: R. Titone, D.A. Porraz, D.W. Putnam, R.P. Jacob, W.E. Bauta and D.J. Elzi. Background: Asthma is a heterogeneous disease with multiple clinical phenotypes and endotypes,1 each...
by Maria Zannes | Feb 25, 2026 | Press Releases
Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung SAN ANTONIO, TX – February 25, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and...
by Maria Zannes | Feb 17, 2026 | Press Releases
Noninvasive CyPath® Lung test has shown 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules less than 2 centimeters Case study highlights how CyPath® Lung reduces patient anxiety and supports physician confidence in assessment...
by Maria Zannes | Feb 9, 2026 | Press Releases
Advisory Board provides independent guidance on strategic priorities, including growing adoption of the Company’s noninvasive CyPath® Lung diagnostic test SAN ANTONIO, Texas – February 9, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology...